Research programme: Huntington's disease gene therapy - Neurologix
Alternative Names: AAV-dXIAPLatest Information Update: 10 Jun 2014
At a glance
- Originator Neurologix
- Class Gene therapies
- Mechanism of Action Caspase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Huntington's disease
Most Recent Events
- 16 Mar 2012 Discontinued - Preclinical for Huntington's disease in USA (Intracerebral)
- 02 Jun 2011 Preclinical development is ongoing in USA
- 27 May 2011 Aegera Therapeutics has been acquired by Pharmascience